Company: PSTV
Filing Date: 2025-07-21
Form Type: DEF 14A
Source: 0001140361-25-026611
Chunk: 1

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-07-21
Form: DEF 14A
Chunk 1
---
a clinical trial for children with brain cancer, and we anticipate enrollment to commence soon. Our pediatric trial builds on our successful Phase 1 adult glioblastoma trial, which shows substantial safety margins and signals of efficacy. This data was published in early 2025 in the prestigious medical journal, Nature Communications. Our glioblastoma Phase 2 trial, ReSPECT-GBM, continues to enroll patients in 2025. Of note, each of these trials continues to benefit from approximately $25M in aggregate grant support. Since the acquisition of CNSide, we have laid the groundwork for a successful relaunch of CNSide in the US. Our preparatory activities are largely complete and we plan to reintroduce the product in Texas in the second half of 2025, extending that launch to all 50 states thereafter. Furthermore, in the past year, we achieved a number of key milestones for CNSide. First, we published multiple scientific articles highlighting the clinical value of CNSide. Second, the CNSide core test is now included in the National Comprehensive Cancer Center Guidelines. Third, we have completed and presented positive FORSEE clinical trial results. Fourth, we have built out a centralized testing laboratory in Houston and validated key commercial elements such as pricing and reimbursement. Finally, we have hired an experienced diagnostics executive team to lead Plus Therapeutics’ CNSide commercial subsidiary. We continue to believe that our CNSide platform uniquely fills a $6 billion market opportunity in the CNS cancer diagnostic space. Additionally, we have taken action to capitalize the Company beyond our existing grant funding, supporting our capital requirements in the U.S. commercial launch of CNSide, as well as our path to FDA approval of REYOBIQ. We anticipate continued clinical progress for our radiotherapeutic technology and realizing commercial value from our strategic acquisition of CNSide. On behalf of our employees, management and directors, I would like to express our deep appreciation to our stockholders and partners for their help and support in 2024 and beyond.

| Sincerely,                          |
| Marc H. Hedrick, M.D.               |
| President & Chief Executive Officer |

TABLE OF CONTENTS

NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 7, 2025

| PLUS THERAPEUTICS, INC.    
 Headquarters               
 2710 REED ROAD, SUITE 160, 
 HOUSTON, TX 77002          |     | MEETING LOCATION:                          
 www.virtualshareholder